Overview

First-in-human Study in Healthy Subjects

Status:
Completed

Trial end date:
2019-02-22

Target enrollment:

Participant gender:

Summary

This initial Phase I study will evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses of CORT118335, the effect of concomitant administration with food on exposure to CORT118335, and its pharmacological effect in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Corcept Therapeutics

Treatments:

Cortisone
Cortisone acetate
Prednisone